PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
Condition: Actinic Keratosis
MeSH terms: Keratosis, Actinic; Keratosis
Intervention: Ingenol mebutate; Placebo Gel
Intervention description: 0.05% Ingenol mebutate Gel once daily for 2 consecutive days; Gel vehicle of PEP005
Phase: Phase 1
Study type: Interventional
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 24.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This trial will be conducted to explore the biological effects in the skin following
      treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by
      reflectance confocal microscopy.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Male or female subjects at least 18 years of age

          2. Subjects with AK lesions and subclinical AK lesions within a contiguous 25 cm2 area on
             the upper extremity

          3. Subjects must have a 25 cm2 area of normal skin on the inner upper arm

          4. Female subjects must be of either:• Non-childbearing potential, post-menopausal, or
             have a confirmed clinical history of sterility or • Childbearing potential, with a
             confirmed negative urine pregnancy test prior to exposure.

          5. Female subjects of childbearing potential must be willing to consent to using high
             effective methods of contraception

          6. Ability to follow trial instructions and likely to complete all trial requirements

          7. Obtained written informed consent prior to any trial-related procedures

        Exclusion Criteria:

          1. Location of the selected treatment areas:• Within 5 cm of an incompletely healed wound
             or infected area of the skin • Within 10 cm of a suspected basal cell carcinoma (BCC)
             or squamous cell carcinoma(SCC)

          2. History or evidence of skin conditions other than the trial indication that would
             interfere with evaluation of the investigational product

          3. Clinical diagnosis/history or evidence of any medical condition that would expose a
             subject to an undue risk of a significant AE or interfere with assessments of safety
             during the course of the trial, as determined by Investigator clinical judgment

          4. Anticipated need for in-patient hospitalisation or in-patient surgery during the trial
             period.

          5. Current participation in any other interventional clinical trial

          6. Subjects who have received treatment with any non-marketed drug product within the
             last two months

          7. Previous enrolment in this clinical trial

          8. Prohibited Therapies and/or Medications 2 weeks prior to the Screening visit within 2
             cm of selected treatment area:•Cosmetic or therapeutic procedures •Use of
             acid-containing therapeutic products • Use of topical salves or topical steroids

          9. Prohibited Therapies and/or Medications: within 4 weeks prior to the Screening visit:
             • Treatment with immunomodulators, cytotoxic drugs or interferon/interferon
             inducers,systemic medications that suppress the immune system, or with UVB

         10. Prohibited Therapies and/or Medications: within 8 weeks prior to the Screening visit:
             • Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 2 cm of
             the selected treatment areas.

         11. Use of systemic retinoids